Julong Holding Ltd current report, Q3 FY2026

Julong Holding Limited — Form 6-K Summary

Reporting period and context: Filed for September 2026. On September 28, 2026, Julong Holding Limited entered into a securities purchase agreement for a private placement. This filing reports a financing transaction, not periodic operating results.

Transaction and financial impact

  • Gross proceeds: Approximately US$897,750, comprising 750,000 Class A ordinary shares sold at US$0.300 per share and 2,250,000 pre-funded warrants sold at US$0.299 each.
  • Expected net proceeds: Approximately US$828,000 after offering expenses; the filing does not provide a detailed expense breakdown.
  • Warrants: Immediately exercisable at US$0.001 per share, with no stated expiration other than when exercised in full. Exercise of all warrants would issue up to 2,250,000 additional Class A ordinary shares.
  • Use of proceeds: General corporate purposes.
  • Expected closing: On or about September 29, 2026, subject to satisfaction or waiver of agreement conditions.

Operating performance, liquidity, and comparison

The filing provides no revenue, profit, cash-flow, margin, debt, or existing liquidity figures. It does not provide comparable-period operating results or quantify how the financing changes the Company’s overall liquidity.

Outlook, risks, and other matters

  • Closing is not stated as completed and remains conditional.
  • The financing is a private placement exempt from Securities Act registration. The securities and shares issuable upon warrant exercise are unregistered and subject to restrictions on resale absent registration or an applicable exemption.
  • The filing gives no business forecast or management outlook beyond the intended general-corporate use of proceeds.
  • The report and attached exhibits are incorporated by reference into the Company’s specified Form F-3 registration statement, as amended.

Investor verification points

  • Confirm whether the placement closed and the final proceeds and offering expenses.
  • Review the warrant and purchase agreement exhibits for additional terms, including any transfer, adjustment, or other provisions.
  • Assess potential dilution against the Company’s outstanding share count and any other convertible or equity-linked securities; those figures are not provided in this filing.
  • Track how proceeds are used and whether the financing materially changes the Company’s liquidity position.